Methylethyltryptamine
Chemical compound From Wikipedia, the free encyclopedia
Methylethyltryptamine (MET), also known as N-methyl-N-ethyltryptamine (N,N-MET), is a serotonergic psychedelic of the tryptamine family.[1][2] It is closely related to dimethyltryptamine (DMT) and to diethyltryptamine (DET).[3][4] The drug acts as an agonist of the serotonin 5-HT2 receptors and to a lesser extent as a serotonin releasing agent.[5]
![]() | |
Clinical data | |
---|---|
Other names | MET; N-Methyl-N-ethyltryptamine; N,N-MET |
Routes of administration | Oral; Vaporized/inhaled |
Drug class | Serotonergic psychedelic; Hallucinogen; Serotonin 5-HT2A and 5-HT2C receptor agonist; Serotonin releasing agent |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C13H18N2 |
Molar mass | 202.301 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
MET has been briefly mentioned in Alexander Shulgin's TiHKAL (Tryptamines I Have Known and Loved) and other publications, where he has stated it to be orally active as a psychedelic at doses of 80 to 100 mg.[1][2] The freebase of MET is active as a psychedelic via vaporization at a dose of 15 mg per a 2011 Erowid trip report.[6] The drug was encountered as a novel designer drug in Europe in 2014.[7]
Interactions
Pharmacology
MET is a serotonin 5-HT2A and 5-HT2C receptor partial agonist.[5] It shows very weak activity as an agonist of the serotonin 5-HT1A and 5-HT2B receptors.[5] In addition to acting at the serotonin 5-HT2 receptors, MET is a serotonin releasing agent with lower potency.[5] It produces the head-twitch response, a behavioral proxy of psychedelic effects, in animals.[4][5]
Chemistry
MET, also known as N-methyl-N-ethyltryptamine, is a substituted tryptamine derivative.[1][2][5] It is closely related to N,N-dimethyltryptamine (DMT) and to other N,N-dialkylated tryptamines.[1][2][5]
Analogues of MET besides DMT include DET, DPT, DiPT, DBT, MiPT, MBT, EPT, EiPT, and PiPT, among others.[1][2] Derivatives of MET include 4-HO-MET, 5-MeO-MET, 5-fluoro-MET, and 7-F-5-MeO-MET.
The lysergamide counterpart of MET is ETH-LAD, an analogue of LSD that was first developed and characterized by Alexander Shulgin.[citation needed]
History
MET appears to have first been described in the literature by 1981.[8] It was specifically mentioned in Michael Valentine Smith's Psychedelic Chemistry.[8] Subsequently, MET was briefly described in Alexander Shulgin's TiHKAL (Tryptamines I Have Known and Loved) in 1997.[1] MET was encountered as a novel designer drug in Europe in 2014.[7]
See also
- Bretisilocin (5-fluoro-MET; GM-2505)
References
External links
Wikiwand - on
Seamless Wikipedia browsing. On steroids.